July 9 (Reuters) - Novartis AG NOVN.S:
SIRONAX GRANTS NOVARTIS EXCLUSIVE OPTION TO ACQUIRE ITS BRAIN DELIVERY PLATFORM WHILE RETAINING RIGHTS TO ADVANCE SELECTED THERAPEUTIC ASSETS
NOVARTIS AG - NOVARTIS WILL EVALUATE BDM PLATFORM WITHIN AN OPTION PERIOD
NOVARTIS AG - SIRONAX IS ELIGIBLE TO RECEIVE UP TO $175 MILLION IN UPFRONT AND NEAR-TERM PAYMENTS
NOVARTIS AG - SIRONAX RETAINS RIGHT TO CONTINUE DEVELOPING SELECTED THERAPEUTIC ASSETS USING PLATFORM